R&D News | pharmaphorum

News

Gilead, Ipsen build the case for their PBC drugs at EASL

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointin

News

First rare disease therapies chosen for FDA START programme

An initiative set up by the FDA to accelerate the development of therapies for rare disease in the same way that Operation Warp Speed delivered COVID-19 vaccine has chosen

News

ASCO: KRAS upstarts set their sights on NSCLC market

There are already two drugs on the market targeting KRAS mutations, for decades considered an undruggable target, but no shortage of drug candidates hoping to follow them.

News

Bayer taps Samsung wearables for menopause sleep study

Sleep disturbances are one of the most common and disruptive symptoms in menopausal women, but not enough is known about the causes, and current sleep aids are often ineff

News

ASCO: Moderna may file melanoma vaccine on phase 2b data

New data from a phase 2b trial of Moderna and MSD’s neoantigen melanoma vaccine may be strong enough to consider filing for accelerated approval before a phase 3 programme

News

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myel

Gilead, Ipsen build the case for their PBC drugs at EASL

First rare disease therapies chosen for FDA START programme

ASCO: KRAS upstarts set their sights on NSCLC market

Bayer taps Samsung wearables for menopause sleep study

ASCO: Moderna may file melanoma vaccine on phase 2b data

ASCO: DREAMM-8 data puts GSK’s Blenrep back on track

UK's Claret Capital raises €575m for European biotechs

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks